Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Drew Wilkins

Physician Assistant Round Rock, TX Physician Assistant

NPI 1598310021 CMS profile 11090360

16040 Park Valley Dr Ste 111, Round Rock, TX 78681

Open in the dashboard

General payments

$8,710

360 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Drew Wilkins of Round Rock, TX is reported in the CMS Open Payments database as having received $8,710 across 360 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,829 75
2024 General $2,120 76
2023 General $1,631 63
2022 General $1,523 71
2021 General $1,608 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Drew Wilkins
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Drew Wilkins were reported at $1,829. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Drew Wilkins Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,608 $132 $37–$438 $132
2022 $1,523 $155 $48–$522 $149
2023 $1,631 $167 $52–$557 $160
2024 $2,120 $178 $55–$600 $164
2025 $1,829 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $1,582 19 payments
  2. AbbVie, Inc. $1,303 57 payments
  3. Janssen Biotech, Inc. $1,142 58 payments
  4. Sumitomo Pharma America, Inc. $662 49 payments
  5. Teleflex LLC $575 8 payments
  6. Astellas Pharma US Inc $527 23 payments
  7. Allergan Inc. $413 20 payments
  8. Antares Pharma, Inc. $325 18 payments
  9. Endo Pharmaceuticals Inc. $261 19 payments
  10. AstraZeneca Pharmaceuticals LP $218 9 payments
  11. Other $1,701 80 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,859 349 payments
  2. Travel and Lodging $606 6 payments
  3. Education $245 5 payments
Products named General payments · program years 2021–2025
  1. INTERSTIM $1,438 18 payments
  2. ERLEADA $969 53 payments
  3. BOTOX Botox Therapeutic $790 38 payments
  4. BOTOX Hyperhydrosis $497 32 payments
  5. XIAFLEX $476 24 payments
  6. GEMTESA $452 38 payments
  7. UroLift System $385 5 payments
  8. BOTOX Urology $383 5 payments
  9. ORGOVYX $377 20 payments
  10. AVEED $310 20 payments
  11. Other $3,917 185 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

2,910

Median for Physician Assistant: 241

Drug cost

$596,997

Median for Physician Assistant: $4,110

Branded share of claims

47.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 309 $257,034
Gemtesa Vibegron Brand 172 $156,429
Elmiron Pentosan Polysulfate Sodium Brand 19 $66,736
Mirabegron Er Mirabegron Brand 50 $39,682
Estradiol Generic 350 $21,196
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 213 $7,873
Solifenacin Succinate Generic 166 $7,305
Fosfomycin Tromethamine Generic 39 $5,511
Potassium Citrate Er Potassium Citrate Brand 41 $5,133
Oxybutynin Chloride Er Oxybutynin Chloride Brand 191 $4,879

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$82,238

Of which drugs: $3,940

Medicare patients

548

Average age 75

Services billed

3,449

286 women, 262 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 32%
Diabetes 28%
Depression 26%
Cancer 24%
Chronic kidney disease 20%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ceftriaxone sodium, per 250 mg J0696 Office 13 52 $19

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $286
$286 — —
ERLEADA
  • Janssen Biotech, Inc. $182
$182 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $164
$164 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $109
$109 172 —
LYNPARZA
  • Merck Sharp & Dohme Corporation $82
  • AstraZeneca Pharmaceuticals LP $23
$105 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

360 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record